Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Colistin→

Colistin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1264-72-8
Molecular formula
C52H98N16O13
Molecular weight
1155.4 g/mol
Drug class
Polymyxin E cyclic lipopeptide antibacterialouter-membrane disruptor
Mechanism of action
Binds lipopolysaccharide and phospholipids in the outer membrane of Gram-negative bacteria, displacing stabilising divalent cations and disrupting membrane integrity, causing leakage of intracellular contents and bacterial death.
Indications / reported uses
  • Treatment of serious infections caused by susceptible multidrug-resistant Gram-negative bacteria, including Pseudomonas aeruginosa, Acinetobacter baumannii and selected Enterobacterales, using systemic formulations under specialist supervision
  • Topical or otic formulations have separate route-specific indications; systemic use is limited by nephrotoxicity and neurotoxicity

Sources: US DailyMed — Colistimethate sodium/colistin products · NLM MeSH — Colistin · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Polymyxin E cyclic lipopeptide antibacterial; outer-membrane disruptor

Mechanism of action

Binds lipopolysaccharide and phospholipids in the outer membrane of Gram-negative bacteria, displacing stabilising divalent cations and disrupting membrane integrity, causing leakage of intracellular contents and bacterial death.

General use cases

  • Treatment of serious infections caused by susceptible multidrug-resistant Gram-negative bacteria, including Pseudomonas aeruginosa, Acinetobacter baumannii and selected Enterobacterales, using systemic formulations under specialist supervision
  • Topical or otic formulations have separate route-specific indications; systemic use is limited by nephrotoxicity and neurotoxicity

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Colistin Environmental Risk Assessment (ERA) (the Colistin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.